研究発表 - 長島　健悟

Recurrence-free survival as a surrogate for overall survival in esophageal squamous cell carcinoma: Nationwide real-world data from Japan

Okui J, Nagashima K, Matsuda S, Sato Y, Okamura A, Kawakubo H, Muto M, Kakeji Y, Kono K, Takeuchi H, Watanabe M, Doki Y, Bamba T, Fukuda T, Fujiwara H, Sato S, Noma K, Miyata H, Fujita T, Kitagawa Y

ASCO 2024 Gastrointestinal Cancers Symposium, 

2024年01月

, 

ポスター発表

• Access to Document (DOI)

Impact of PD-L1 expression on survival in patients with unresectable/recurrent gastric cancer receiving first-line chemotherapy without immune checkpoint inhibitors

Hirano H, Yamada Y, Nagashima K, Hiraoka N, Sekine S, Takahashi N, Azuma M, Iwasa S, Kanato K, Machida N, Kinoshita T, Hata H, Kawakami H, Takahari D, Ojima T, Kadowaki S, Boku N, Kurokawa Y, Terashima M, Yoshikawa T

ASCO 2024 Gastrointestinal Cancers Symposium, 

2024年01月

, 

ポスター発表

• Access to Document (DOI)

FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF, FLOT therapy for locally advanced esophageal carcinoma (JCOG1804E)—Primary safety and short-term efficacy results for cohort E

Yoshii T, Yamamoto S, Kato K, Daiko H, Hara H, Kojima T, Abe T, Tsubosa Y, Kawakubo H, Fujita T, Kadowaki S, Tsushima T, Matsuda S, Nagashima K, Aoki K, Yachida S, Kitagawa Y

ASCO 2024 Gastrointestinal Cancers Symposium, 

2024年01月

, 

ポスター発表

• Access to Document (DOI)

The FSTL1-DIP2A axis as a promising target in the anti-PD1 therapy of advanced gastric cancer

Kudo-Saito C, Boku N, Shoji H, Imazeki H,Nagashima K, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Aoki K, Muro K

SITC 38th Annual Meeting (SITC 2023), 

2023年11月

, 

口頭発表（一般）

• Access to Document (DOI)

First-line treatment with CET/PAN vs. BEV in elderly patients with RAS WT mCRC: A multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum

Yamamoto K, Hirose T, Takashima A, Yamazaki K, Yukami H, Uetake H, Tsuda M, Suto T, Moriwaki T, Sugimoto N, Ojima H, Takii Y, Yasui H, Esaki T, Tsuji A, Goto M, Sawada R, Otsu S, Shinozaki K, Nagashima K, Shimada Y.

ESMO Congress 2023, 

2023年10月

, 

ポスター発表

• Access to Document (DOI)

A phase I study of pevonedistat plus capeOX in patients with advanced gastric cancer refractory to platinum (NCCH-1811)

Takahari D, Shoji H, Ooki A, Hirano H, Okita NT, Nagashima K, Adachi J, Yamaguchi K, Kato K, Boku N

ESMO Congress 2023, 

2023年10月

, 

ポスター発表

• Access to Document (DOI)

Tumor response as a predictor of survival for RAS-WT left-sided mCRC administered first-line molecularly targeted drugs: An observational study by the Japanese Society for Cancer of the Colon and Rectum

Hirose T, Takashima A, Yamazaki K, Yukami H, Uetake H, Tsuda M, Suto T, Moriwaki T, Sugimoto N, Ojima H, Takii Y, Yasui H, Esaki T, Tsuji A, Goto M, Sawada R, Otsu S, Shinozaki K, Nagashima K, Shimada Y.

ESMO Congress 2023, 

2023年10月

, 

ポスター発表

• Access to Document (DOI)

CIDP/抗MAG抗体関連ニューロパチー/MMN全国疫学調査 二次調査結果報告

青墳 佑弥, 澁谷 和幹, 三澤 園子, 水地 智基, 狩野 裕樹, 諸岡 茉里恵, 大谷 亮, 大櫛 萌子, 松井 麻貴, 長島 健悟, 佐藤 泰憲, 栗山 長門, 桑原 聡

臨床神経学, 

2023年09月

, 

(一社)日本神経学会

Tumor response as a predictor of survival for RAS-WT left-sided mCRC administered first-line molecularly targeted drugs: An observational study by the Japanese Society for Cancer of the Colon and Rectum

T. Hirose, A. Takashima, K. Yamazaki, H. Yukami, H. Uetake, M. Tsuda, T. Suto, T. Moriwaki 7 , N. Sugimoto, H. Ojima, Y. Takii, H. Yasui, T. Esaki, A. Tsuji, M. Goto, R. Sawada, S. Otsu, K. Shinozaki, K. Nagashima, Y. Shimada

ESMO 25th World Congress on Gastrointestinal Cancer 2023, 

2023年06月

-

2023年07月

, 

ポスター発表

First-line treatment with CET/PAN vs. BEV in elderly patients with RAS WT mCRC: A multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum

K. Yamamoto, T. Hirose, A. Takashima, K. Yamazaki, H. Yukami, H. Uetake, M. Tsuda, T. Suto, T. Moriwaki, N. Sugimoto, H. Ojima, Y. Takii, H. Yasui, T. Esaki, A. Tsuji, M. Goto, R. Sawada, S. Otsu, K. Shinozaki, K. Nagashima, Y. Shimada

ESMO 25th World Congress on Gastrointestinal Cancer 2023, 

2023年06月

-

2023年07月

, 

ポスター発表

Expression molecular subtype as a predictor of outcomes of chemoradiotherapy for esophageal cancer

Manabu Muto, Keiko Minashi, Tomonori Yano, Yusuke Amanuma, Ryu Ishihara, Akinori Watanabe, Chikatoshi Katada, Tomoki Yamatsuji, Kayoko Matsushima, Hisashi Doyama, Takayuki Ando, Yasumasa Nishimura, Katsuyuki Sakanaka, Shigeru Tsunoda, Shinya Ohashi, Juko Shimizu, Harue Tada, Ryuji Uozumi, Kengo Nagashima, Hiroki Sasaki

2023 ASCO Annual Meeting, 

2023年06月

, 

ポスター発表

Development of an artificial intelligence algorithm for adjuvant chemotherapy based on a nationwide registry of patients with gastric cancer by the Japanese Gastric Cancer Association (JGCA).

Yasuhide Yamada, Ami Kamada, Yoshinori Kabeya, Sumito Yoshida, Hitoshi Harada, Naoki Urakawa, Shingo Kanaji, Yuma Nakamura, Kengo Nagashima, Hiroya Takeuchi, Yuichiro Doki, Yuko Kitagawa, Yasuhiro Kodera, Yoshihiro Kakeji

Journal of Clinical Oncology, 

2023年06月

, 

American Society of Clinical Oncology (ASCO)

　概要を見る

4063

Background: Recent marked advances in machine learning have led to expectations of the clinical application of artificial intelligence (AI) to support medical care. Methods: A survival analysis model which consisted of 31 covariates was adopted for AI algorithms using machine learning and these were constructed using clinical data sets for training. The performance of AI algorithms was evaluated in order to determine the optimal chemotherapy including surgery alone without any adjuvant chemotherapy with the highest survival rate for each patient. This involved using clinical data for verification to compare survival of an AI-recommended treatment group, for which therapy recommended by AI was actually administered, with an AI-deprecated group, for which therapy recommended by AI was not administered. Results: The clinical characteristics of 23653 patients and treatment are described in the Table from 2011 to 2018 in a nationwide registry of gastric cancer patients in Japan by the Japanese Gastric Cancer Association and were made available for this study. S-1 monotherapy was used the most frequently of all adjuvant chemotherapy in this study. We used the "restricted mean overall survival time" (RMST) of all the patients as metrics. The RMST in the AI-recommended and the AI-deprecated groups were 51.4 and 47.5 months, respectively. Patient data for the verification were matched baseline characteristics by the propensity score. This model predicted effectively overall survival after gastrectomy. The RMST of over 80 years old patients were 43.9 in the AI-recommended and 38.3 months in the AI-deprecated, respectively. This AI algorithm recommended adjuvant S-1 more frequently for patients with higher age, male, American Society of Anesthesiologists – physical status 2, Eastern Cooperative Oncology Group performance status 1, pT3/pT4, pN2/pN3, more than the upper normal limit of preoperative blood urea nitrogen, macroscopic types 2/3, differentiated adenocarcinoma, Roux-en-Y reconstruction, and Clavien-Dindo classification grade II/III. The RMST for pStage IIA/IIB/IIIA/IIIB/IIIC were 55.7/53.9/50.3/45.7/42.2 months in the AI-recommended and 55.1/50.7/43.9/36.9/32.0 months in the deprecated. This AI algorithm showed a higher survival rate in pStage III patients particularly. Conclusions: The AI algorithm could readily be integrated into clinical practice to choose adequate adjuvant chemotherapy for each patient based on each patient's baseline data because it trained and verified the nationwide registry has good predictive performance. [Table: see text]

LAG3-related factors to predict response to nivolumab monotherapy in advanced gastric cancer (WJOG10417GTR study)

Tsugaru K, Boku N, Kudo-Saito C, Shoji H, Imazeki H, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Nagashima K, Aoki K, Muro K

ASCO 2023 Gastrointestinal Cancers Symposium, 

2023年01月

, 

ポスター発表

• Access to Document (DOI)

CIDP/抗MAG抗体関連ニューロパチー/MMN全国疫学調査 一次調査結果報告

青墳 佑弥, 澁谷 和幹, 三澤 園子, 狩野 裕樹, 諸岡 茉里恵, 大谷 亮, 大櫛 萌子, 長島 健悟, 栗山 長門, 桑原 聡

末梢神経, 

2022年12月

, 

日本末梢神経学会

Association between endogenous subtype classification for esophageal squamous cell carcinoma and outcome of chemoradiotherapy

Yano T, Amanuma Y, Minashi K, Komatsu M, Nagashima K, Shimizu J, Ishihara R, Watanabe A, Yamatsuji T, Matsushima K, Doyama H, Ando T, Nishimura Y, Sasaki H, Muto M

The 18th ISDE World Congress for Esophageal Diseases, 

2022年09月

, 

ポスター発表

• Access to Document (DOI)

Prognostic impact of myeloid subsets in nivolumab monotherapy for advanced gastric cancer (WJOG10417GTR study)

Boku N, Kudo SC, Imazeki H, Shoji H, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Nagashima K, Aoki K, Muro K

ESMO Congress 2022, 

2022年09月

, 

ポスター発表

• Access to Document (DOI)

Profiling of myeloid cells associated with prognosis in nivolumab monotherapy for advanced gastric cancer (WJOG10417GTR study)

Shoji H, Boku N, Kudo-Saito C, Nagashima K, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T, Okano M, Narita Y, Yamamoto Y, Kizawa R, Imazeki H, Aoki K, Muro K.

ESMO Congress 2022, 

2022年09月

, 

ポスター発表

• Access to Document (DOI)

Effect of adjuvant chemotherapy in patients with stage III colon cancer based on the Multi-Institutional Registry of Large Bowel Cancer in Japan

Yamada Y, Kobayashi H, Nagashima K, Sugihara K

2022 ASCO Annual Meeting, 

2022年06月

, 

ポスター発表

• Access to Document (DOI)

WJOG13219G: Triplet versus doublet in patients with previously untreated BRAFV600E-mutant metastatic colorectal cancer: A multi-institutional real-world data analysis (BRACELET study)

Shimozaki K, Hirata K, Sato T, Nakamura M, Kato K, Hirano H, Kumekawa Y, Hino K, Kawakami K, Kito Y, Matsumoto T, Kawakami T, Komoda M, Nagashima K, Sato Y, Yamazaki K, Hironaka S, Hamamoto Y, Takaishi H, Muro K

ASCO 2022 Gastrointestinal Cancers Symposium, 

2022年01月

, 

ポスター発表

FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF, FLOT therapy for locally advanced esophageal carcinoma (JCOG1804E)—Short-term results for cohorts C and D.

Matsuda S, Yamamoto S, Kato K, Daiko H, Kojima T, Hara H, Abe T, Tsubosa Y, Kawakubo H, Nagashima K, Aoki K, Yachida S, Kitagawa Y

ASCO 2022 Gastrointestinal Cancers Symposium, 

2022年01月

, 

ポスター発表